Compare Amplify Cybersecurity ETF (HACK) vs Moderna, Inc. (MRNA) Price & Performance

HACK trades at $110.08, down 0.86% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX above 60). The ETF benefits from rising cybersecurity spending, which surpassed $300 billion in 2026 (24/7 Wall Street, 2026-07-03), and recently hit a 52-week high (Zacks Investment Research, 2026-05-26). Institutional interest is growing, with D.A. Davidson increasing its stake by 44.8% in Q1 2026 (Defense World, 2026-07-19).

Outlook remains positive due to structural demand for cybersecurity, but risks include sector volatility and reliance on tech spending. The ETF offers exposure to a high-growth theme, yet investors face concentration in tech and sensitivity to corporate budget cycles. Near-term resistance is at $111, with support at $110.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.